Cediranib
Iris Melanoma
National Cancer Institute (NCI)Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Iris Melanoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tyrosinase Peptide National Cancer Institute (NCI) | Phase 3 | BB |
Sargramostim National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | B |
DACARBAZINE National Cancer Institute (NCI) | Phase 2 | B |
gp100 antigen National Cancer Institute (NCI) | Phase 2 | B |
View all 23 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →